Overview
- The company priced 4,551,100 Class A shares at $60 in an upsized offering for expected gross proceeds of about $273.1 million, with a 30‑day underwriters’ option.
- Shares began trading under ticker BLLN and jumped from a $60 offer to a $100 open, finishing the first day at $109 for a market value reported at roughly $5.8 billion.
- BillionToOne develops non-invasive prenatal and oncology blood tests based on its Quantitative Counting Templates platform that counts DNA at the single‑molecule level.
- The company reported $209 million in revenue over the 12 months through June 30 from about 508,000 tests, compared with $153 million in 2024, with losses narrowing in the first half of 2025.
- The listing occurred during a U.S. government shutdown, with reports of SEC guidance allowing pricing flexibility for IPOs, and was led by J.P. Morgan, Piper Sandler, Jefferies and William Blair.